VVOS logo

Vivos Therapeutics, Inc. Stock Price

NasdaqCM:VVOS Community·US$23.9m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author
Create a narrative

VVOS Share Price Performance

US$3.19
0.77 (31.82%)
50.9% undervalued intrinsic discount
US$6.50
Fair Value
US$3.19
0.77 (31.82%)
50.9% undervalued intrinsic discount
US$6.50
Fair Value
Price US$3.19
AnalystHighTarget US$6.50
AnalystConsensusTarget US$5.10
AnalystLowTarget US$4.00

VVOS Community Narratives

AnalystHighTarget·Updated
Fair Value US$6.5 50.9% undervalued intrinsic discount

Rising Sleep Apnea Prevalence Will Accelerate Noninvasive Treatment Expansion

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value US$5.1 37.5% undervalued intrinsic discount

FDA Clearance And New Deployments Will Expand Non-Invasive Sleep Care

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystLowTarget·Updated
Fair Value US$4 20.3% undervalued intrinsic discount

Rising Debt And Regulatory Risks Will Limit Healthcare Expansion

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent VVOS News & Updates

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected

Jul 02
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected

Vivos Therapeutics, Inc. Key Details

US$14.4m

Revenue

US$6.3m

Cost of Revenue

US$8.0m

Gross Profit

US$22.4m

Other Expenses

-US$14.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-1.91
Gross Margin
55.91%
Net Profit Margin
-99.50%
Debt/Equity Ratio
172.7%

Vivos Therapeutics, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Moderate risk and slightly overvalued.

5 Risks
1 Reward
View Full Analysis

About VVOS

Founded
2016
Employees
113
CEO
R. Huntsman
WebsiteView website
www.vivos.com

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Market Insight

Header cover image

✨Rare Earths: Tiny Market, Outsized Influence

Richard Bowman avatarRichard Bowman
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Last Week
⚡ Utilities: Defensive Dividends Meet the AI Power Surge

⚡ Utilities: Defensive Dividends Meet the AI Power Surge

U.S. Market Performance

  • 7 Days: 1.2%
  • 3 Months: 8.5%
  • 1 Year: 17.7%
  • Year to Date: 14.8%
Over the last 7 days, the market has risen 1.2%, driven by gains of 2.4% in the Information Technology sector. The market is up 18% over the last 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›